STRATEGIC MARKETING INNOVATIONS

Lobbying for TONIX PHARMACEUTICALS · Clinical-stage biopharmaceutical company

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · Massachusetts · House · Senate · $40,000.00 income · posted Jul 17, 2026

Lobbying activity 2

Health Issues

Patient access to non-opioid analgesic drug treatments. Biodefense countermeasures fundings.

Defense

Patient access to non-opioid analgesic drug treatments. Biodefense countermeasures fundings.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.